Cancer Immunity (29 January 2010) Vol. 10, p. 4

Cancer Immunity (7 January 2010) Vol. 10, p. 1

Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each t...

Cancer Immunity (15 January 2013) Vol. 13, p. 3

1Department of Oncology, University Hospital Zürich, Zürich, Switzerland 2CT-Atlantic, Schlieren, Switzerland 3Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan-Kettering Cancer Center, New York, NY, USA 4Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan 5Departments of Cancer Vaccine and Immuno-Gene Therapy, Mie University Graduate...

Cancer Immunity 13:6 (2013)

1Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA 2Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA 3Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA 4Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA *Present address: Eppley Institute for Research in Cancer, Universit...

Cover Vol. 7, No.2, June 2010

Cancer Immunity (22 March 2006) Vol. 6, p. 6

1Multidisciplinary Oncology Centre (CePO), Lausanne, Switzerland 2Ludwig Institute for Cancer Research (LICR), Lausanne Branch, Lausanne, Switzerland 3Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland 4National Centre for Competence in Research (NCCR) Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Swi...